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Dendritic cells (DCs) are a heterogeneous population of antigen-presenting cells derived from hematopoietic progenitors
that bridge the transition between the innate and adaptive immune responses, while maintaining self-tolerance and Th1/Th2
homeostasis, by priming other cells in either an immunogenic or tolerogenic direction. Through their role in both innate and
adaptive immunity, DCs play a major part in transplant engraftment and rejection and in graft-versus-host disease (GvHD).
Preferentially tolerogenic or immunogenic DC subtypes oﬀer targets for immunotherapy, to optimize transplant success rates
and prolong disease-free and overall survival. Cord blood DCs are immature and preferentially tolerogenic, due to maternal-fetal
tolerance, leading to better graft acceptance and immune reconstitution and explaining the lower incidence and severity of GvHD
in CB transplantation, despite donor-host mismatching. Manipulation of DC maturation and cell loading with tumor-antigens
can direct antitumor immunity and target minimal residual disease, as demonstrated for acute myeloid leukemia, optimizing the
graft-versus-leukemia eﬀect.
1.DendriticCells
Dendritic cells (DCs) are a heterogeneous population of
potent lineage-negative HLA-DR+ antigen-presenting cells
(Apcs), derived from CD34+ hematopoietic progenitors that
are present in small numbers in solid tissues and peripheral
blood, and that bridge the transition between the innate
immune response and adaptive responses, through their
activation of CD4+ T-cells, CD8+ T-cells, and B-cells, while
maintaining self-tolerance.
Recent data suggest that DCs arise from multilym-
phoid progenitors, along with lymphoid cells, monocytes,
and macrophages [1], contradicting the classic and widely
accepted model of early lymphoid-myeloid lineage segre-
gation between the two main DC subsets, which can be
diﬀerentiated through the expression of the inactivated-C3b
receptor 4 (complement transmembrane protein) integrin
alphaXchain(ITGAXorCD11c).Thismodelpostulatesthat
CD11c− CD123high CD33− CD16− plasmacytoid dendritic
cells (pDc) derive from a lymphoid progenitor cell, whereas
CD11c+ CD123dim CD33+ CD16− myeloid dendritic cells
(mDc) originate in a myeloid precursor cell [2–4]; the mDc
subset can be further divided into distinct subpopulations,
accordingtotheexpressionofblooddendriticcellantigens—
BDCA1+ (CD1c+) DC and BDCA3+ (CD141+) DC. The
remainingBdcas,BDCA2,andBDCA4areexpressedbypDc
[4]. A third subtype of DC with a distinct immunophe-
notype has been described, comprising monocytoid-related
CD16+ CD14−/low CD123inter CD33inter DC, with a possible
originindiﬀerentiatedmaturemonocyteswhichhavedown-
regulated or lost the monocyte marker CD14 [5–7].
Myeloid dendritic cells (also called DC 1) express toll-
like receptor (Tlr)2a n dTlr 4 and secrete Il-12, which
alters the Th-cell balance in a Th1 direction, while pDc( also
known as DC 2), physiologically residing in primary and
secondary lymphoid organs, express Tlr 7a n dTlr 9a n d
secrete type I interferons (Ifn) and prime a Th2 response.
The latter subtype, through its ability to diﬀerentiate in vitro
into mature classic DC, would provide the link between
the innate response and the adaptive one [8]. The balance
between Th1- and Th2-type immunity is thus dependent on
the equilibrium between the diﬀerent subsets of DC, the loss
of which could lead to immune dysregulation, as suggested
by observations of an epidemiological inverse relationship2 Stem Cells International
between infancy/childhood infections and an atopic poten-
tial,thebasisoftheso-called“hygienehypothesis”[9],which
is still controversial.
The pathogenic role of DC dysfunction (and its role
as a potential therapeutic target) is the focus of continuing
research, with descriptions of DC involvement in pathologic
changes which have been associated with Th1/Th2 dysreg-
ulation, such as autoimmune disease (including rheumatic,
neurologic and endocrine diseases [10–12], characterized
by a Th1 response [13]) and allergy (including asthma,
atopic dermatitis, and drug hypersensitivity [14–16], with a
skew towards Th2 [13, 17]), and pDc being implicated in
diseases with a Type I Ifn-signature [18]. The rebalancing
of Th1- and Th2-type responses, through Th2 stimulation in
autoimmunity and Th1 shift in allergy, could be harnessed
therapeutically [9, 19, 20]. Han et al. highlighted the role
of DC in the re-regulation of the Th2 shift in allergy,
by showing that DC isolated from Chlamydia muridarum-
infected mice could inhibit allergen-induced systemic and
local eosinophilia, on adoptive transfer [20].
The applications of immunotherapeutic DC vaccination,
as a way of enhancing host anticancer immunity, is another
developing ﬁeld; the administration of DC loaded with
leukemic cell antigens is a promising experimental treatment
for minimal residual disease in acute myeloid leukemia and
was the focus of a recent review by Van Den Ancker et al.
[21].
Antigen presentation by DC can direct immune
responses in both an immunogenic (stimulatory) and a tol-
erogenic direction [22], with various stages of maturation
being associated with opposing functions. In a steady
state, DC help to maintain self-tolerance, which is a cen-
tral issue in immune homeostasis; in tissues, challenge by
pathogens with stimulation of pattern-recognition receptors
induces the maturation of immature sentinel resident DC,
which then migrate towards the draining lymph nodes to
present antigens to T cells and prime an adaptive speciﬁc
response.However,thetraditionalviewofaclearsegregation
between immature/tolerogenic and mature/immunogenic
capabilities seems not to be a correct representation of
DC function [23]; the induction of tolerance has been
reported in immature, and partially mature DC pheno-
types (similar to steady-state migratory veiled DC which
tolerize lymph node T-cells towards self), whereas only
the fully mature stage of DC diﬀerentiation would be
immunogenicandabletoreleaseproinﬂammatorycytokines
[24], with inﬂammatory stimuli converting a tolerogenic
signal to a stimulatory one [22]. Current knowledge
suggests that the induction of regulatory T cells (Treg),
and not just the lack of inﬂammatory signals, contrib-
utes to the maintenance of tolerance by immature DCs
[3, 23].
Various authors have shown that DC maturity/imma-
turity can be manipulated, further optimizing the im-
munotherapeutic potential of these cell populations. DC
maturation can be stimulated in vitro with increasing
concentrations of growth hormone, resulting in increased
Il-12 secretion and increased lymphocyte activation [25],
with a Th1 shift, while the early addition of tumour-necrosis
factor alpha (Tnf-α) to umbilical cord blood (cord blood,
Cb) mononuclear cell cultures enhances cell survival and
increases DC maturation markers (CD80,C D 83,C D 86, and
Hla-Dr), also heightening Il-12 secretion by mature DC
[26].
2.DendriticCells inTransplantation
One of the main complications of solid organ trans-
plantation is the rejection of the engrafted tissue by the
host’s immune system, with loss of function. In allogeneic
hematopoietic stem cell or bone marrow transplantation
(allo-Bmt), the opposite can also happen, with the engrafted
tissue rejecting the host’s immune system, a phenomenon
known as graft-versus-host disease (GvHD), which is
responsible for a signiﬁcant fraction of morbidity and both
early [27] and late post-transplant death [28], due to organ
damage and infection, in a context of immunodeﬁciency. A
timeline has been used to separate acute GvHD (aGvHD),
which takes place up to 100 days post-transplant and
typicallyinvolvesskin,thegastrointestinaltract,andtheliver,
from chronic (cGvHD) starting from the 100th day onward;
cGvHD presents with a generalized systemic involvement
and shares many of its features with autoimmune diseases,
suggesting diﬀerent pathogenic events from aGvHD [29].
The importance of DC and the Th1/Th2 homeostasis in
autoimmunity has been described above.
The engrafted immune system, however, can also mount
a response against the host’s leukemic clone, a beneﬁcial
immunotherapeuticeﬀectofallo-Bmtdescribedasthegraft-
versus-leukemia (GvL) eﬀect, which can reduce primary
disease relapse rates [30] but is diminished by the eﬀort to
combat GvHD, since part of the GvL eﬀect is proportionally
related to the intensity of GvHD [31, 32]. The beneﬁt of
the decrease in relapse rates due to GvL can be diluted
by the increase in early and late death caused by GvHD,
resultinginnoeﬀectonoverallsurvival.Astherealsoappears
to be a direct antileukemic eﬀect which is independent of
GvHD [32], stem-cell transplantation should ideally evolve
to exploit this eﬀect while diminishing the impact of GvHD,
to improve disease-free survival and overall survival.
Alloreactive T cells are responsible for the rejection of
allografts through major histocompatibility complex (Mhc)
cross-recognition. GvHD is due to donor (graft) T-cell
recognition of Mhc and minor histocompatibility antigen
(miHAg) mismatches between graft and host, with aGvHD
depending on donor CD8+ T-cells and cGvHD originating
with donor CD4+ T-cells [33, 34].
The in vitro and ex vivo manipulation of the stage of DC
maturation, with a selection of the tolerogenic preferentially
immature stage, has previously been shown to be able to
induce allotolerance by speciﬁcally targeting alloreactive T-
cells, suggesting a role for the use of manipulated donor or
recipient DC in the management of transplant engraftment
and rejection [35]. Animal models of solid organ trans-
plantation have shed light on the importance of DC in
alloimmunity; in rats, the transplantation of a donor heart
deprived of its DC population and repopulated with host-
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found, instead, an acute rejection of the organ, starting in
situ in the donor [36], demonstrating that both host and
donorimmunecellsplayanimportantroleinGvHD.Several
published studies have further clariﬁed the role of donor and
host Apcs. In the murine model, it has been shown that,
immediately after transplantation, and before clearance of
host DC, the latter activate donor CD8+ T cells which, in
turn, start the aGvHD response [33, 34, 37]. cGvHD, on the
o t h e rh a n d ,a p p e a r st ob ed e p e n d e n to ne i t h e rh o s to rg r a f t
Apcs[ 33, 34]. In humans, the role of DC in transplantation
is perhaps best exempliﬁed by the rapid acute rejection of
skin allografts, which has been attributed to the skin’s rich-
ness in a resident skin-homing DC population (Langerhans’
cells) [38], and which has limited the ﬁeld of skin transplan-
tation. The early ﬁnding that the immunosuppressive anti-
GvHD drug sirolimus (rapamycin) exerts its eﬀect through
DC modulation (including modulation of maturation [39],
macropinocytosis and endocytosis [40], antigen uptake [41],
and signaling and apoptosis [42–44]) further emphasized
the role of Dc in the GvHD response. Klangsinsirikul et
al. have supported the previous ﬁndings by showing that
the elimination of the host Apcs diminishes the intensity of
GvHD [45], while Sato and colleagues have shown that host-
derived regulatory DC (Dcreg) generated in vitro that express
Mhc Class II and lack expression of immune costimulatory
molecules were more eﬀective in preventing GvHD than
classic tolerogenic DC, through the induction of T-cell
anergy due to diminished co-stimulation, despite the pres-
ence of a potent antigenic signal [46, 47]. The same authors
identiﬁedanaturallyoccurringpopulationofDcreg (CD49b+
CD200R3+)inamurinemodelof Mhc-compatible,miHAg-
incompatible allo-Bmt, which suppressed cutaneous cGvHD
through a decrease in proinﬂammatory cytokines and a
diminished donor CD4+ T-cell alloreaction [48]. Their work
in a murine model has also shown that Dcreg cells are
associated with a decreased rate of post-transplant leukemic
relapse, demonstrating the possibility of obtaining a strong
GvL eﬀect separate from the GvHD response [46]a n d
further highlighting the importance of the manipulation
of DC subpopulations as a way to increase disease-free
survival in progenitor cell transplantation. In fact, recent
studies [49, 50] have identiﬁed a population of CD8α+ T-
cell receptor (TCR)− facilitating cells (FCs) that enhance
allo-Bmt engraftment and tolerance, and decrease GvHD,
and have characterized the main subpopulation of FC as
plasmacytoid precursor dendritic cells (p-preDCs) which
can induce antigen-speciﬁc Treg.
Tolerogenic DC, through their ability to induce Treg
expansion, have also been shown to confer protection
from autoimmune diseases. Il-10, transforming growth
factor beta (Tgf-β), granulocyte colony-stimulating factor
(G-Csf), hepatocyte growth factor (Hgf), and vasoactive
intestinal peptide (Vip) have all been found to modulate
DC maturation, favoring the diﬀerentiation of tolerogenic
DC, an ability which may be harnessed therapeutically for
the treatment or prevention of autoimmunity, graft rejection
and GvHD [23].
3. DendriticCells inCord
Blood Transplantation
Immunologically, umbilical Cb diﬀers from adult peripheral
blood, as a consequence of its function, simultaneously
reﬂecting the need to prevent mother/fetus alloimmuniza-
tion and the diminished immune stimulation due to the
reduced antigenic load of the intrauterine environment.
Among the diﬀerences described are a diminished per-
centage of DC and speciﬁc CD14+ monocyte subsets [51];
nevertheless, Cb is a rich source of hematopoietic stem cells
and progenitor cells, and immune cells (including DC) at
an immature stage of diﬀerentiation. In fact, the phenotype
of fetal and neonatal/infant DC (as determined by ﬂow
cytometry) is skewed towards immaturity, when compared
with adult DC, with a suggestion of decreased ability to
take up antigens through IgG-mediated mechanisms (as
revealedbyadecreasedexpressionoftheIgGreceptorsCD32
and CD64) and reduced co-stimulation [52]. A decrease in
co-stimulation was one of the characteristics identiﬁed by
Sato et al., in Dcreg, in the studies described above [46–
48]. Furthermore, other authors have found that Cb DCs
secrete less Tnf-α and Ifn-α, after stimulation, than Pb DCs
[51]. Plasmacytoid and mDc responses to Tlr 4 agonists
(bacterial lipopolysaccharide) and Tlr 9 agonists (CpG
oligonucleotides) are decreased in the neonate and infant,
when compared to adult responses and increase during the
ﬁrst year of life [53]. Other studies, however, have suggested
that Cb Dc have better antigen-presenting capabilities than
peripheral blood or bone marrow DC,a sr e p r e s e n t e db y
an increase in antigen-positive endosomes on ﬂuorescent
microscopy [54], ﬁndings which can also be viewed in light
of Sato’s description of potent antigen signaling without co-
stimulation [46–48].
The overall status of the fetal/neonatal immune system
seems to be skewed in a Th2 direction, with a decrease in
adaptive responses, which is in part responsible for a height-
ened susceptibility to infections in infancy [55, 56]( a n d
consequent dependence on the mother’s immune system),
but which is necessary to avoid Th1-dependent mother/fetus
alloimmunization [57]; the mature Th1/Th2 balance is
acquired by the na¨ ı v ei m m u n es y s t e mt h r o u g he x p o s u r et o
microbial antigens, a process which is necessary to avoid
immune dysfunction such as allergy or autoimmunity [58],
as previously described.
The diminished tendency for alloimmunization which
is characteristic of Cb could theoretically be harnessed for
transplantation, with reduced alloreactivity between host
and donor. Consequently, human Cb was used for the
ﬁrst time as the source of hematopoietic stem cells for
transplantation just over two decades ago by Gluckman et
al. [59] and, since that ﬁrst description, Cb transplantation
has been observed to be associated with less frequent and
less severe GvHD than allo-Bmt [60], allowing for a higher
degree of mismatching between donor and host.
Several factors have been identiﬁed which contribute to
the decreased incidence of GvHD with Cb, involving both
adaptive and innate immunity, and including phenotypic or4 Stem Cells International
functional immaturity, reduced proinﬂammatory cytokine-
producing T-cell populations and increased immunosup-
pressive factors [61–65]. That the diminished GvHD
response could also in part be due to the diﬀerences in the
DC populations found in the two tissues, is demonstrated
by the diﬀerent expression of the human leukocyte antigen
(Hla)-G [66] and the lower expression of cell-surface mark-
ers involved in DC/T-cell interaction [67]. Cb monocytes
and Cb CD16+ CD14−/low DC p r o d u c el o w e rb a s a ll e v e l s
of cytokines (Il-1β, Il-6, Il-12, and Tnf-α), when compared
to peripheral blood, with identical responses to stimulation,
reﬂecting the reduced antigen stimulation in utero,b u t
suggesting that the ability to respond to stimulation shown
by monocytes and CD16+ CD14−/low DCs reﬂects cellular
maturity [5]. The analysis of the three DC subpopulations
haspointed atlower absoluteandrelative numbersof CD16+
CD123inter CD33inter DCinCb[68],thesubsetthatexpresses
the highest amounts of proinﬂammatory cytokines [69, 70],
which would contribute to the relative immune immaturity
of Cb [68].
Several authors have found a decrease in the frequency of
monocytes expressing Il-12 and Tnf-α in Cb [5, 51],w h i c h
couldhelptoexplainthedecreasedTh1responseandalloim-
munization described for fetal/neonate blood and, conse-
quently, the reduced inﬂammation and diminished GvHD
incidence and severity [5] that has been reported in Cb
transplantation. On the other hand, the factors listed above
can also explain the increased incidence of infectious com-
plications which has been described by some authors in Cb
transplantation [71], a parallel of neonate/infant infectious
susceptibility. The complex relationship between infectious
complications and GvHD was clinically demonstrated by
initial unexpected descriptions of reduced cytomegalovirus
(Cmv) reactivation rates in patients undergoing sirolimus
prophylaxis of GvHD after allo-Bmt, which led Marty et al.
topublisharetrospectiveanalysisthatconﬁrmedaprotective
eﬀect against Cmv [72], a result which could take into
account both the role of Cmv infection on DC function
impairment [73], and the modulatory eﬀects of sirolimus on
DC function, described above.
Adding to the putative causes of the higher Cb trans-
plantation success, is the increase in CXCR4 in Cb attributed
to immune immaturity, and which could lead to improved
engraftment [5] and decreased graft rejection, with a poten-
tial for improving disease-free survival. The described ability
of Cb DCs to eﬃciently induce Treg expansion, despite other
markers of immaturity, contributes to graft tolerance in Cb
allo-Bmt [51].
Immune reconstitution after transplantation has been
compared for Cb and allo-Bmt; Moretta et al. found that
reconstitution was not only comparable between the two
progenitor cell sources, but Cb recipients actually showed
a higher number of B cells, with a better CD4+ T-cell
recovery in unrelated Cb recipients, which the authors
attributed to the decreased GvHD eﬀect [71]. In human
allo-Bmt, Arpinati et al. suggested that DC reconstitution
was impaired by the presence of an aGvHD response, as
well as by steroid treatment [74], which would point at a
bidirectional inﬂuence, with DC regulating GvHD, and the
latter impacting on DC reconstitution. This bidirectional
eﬀect of GvHD on the success of regaining a normal pop-
ulationof DCcouldalsopartlyjustifytheveryhighincidence
of infectious complications described in GvHD [75]. Thus,
Cb transplantation could help to reduce GvHD-related in-
fectious complications, though the positive beneﬁt might be
oﬀset by the infectious susceptibility described above.
Finally, Cb GvL eﬀect has also been favourably compared
to peripheral blood, with recent studies showing that Cb DC
enhance the proliferative capability and antileukemia eﬀect
of Cb cytokine-induced killer (Cik) cells, when compared
to Cb Cik cells alone, with a higher proliferative ability than
peripheral blood DC-Cik cells [76].
Inconclusion,DCpopulations,throughtheircentralrole
in both innate and adaptive immunity, play a major part
in transplant acceptance, engraftment, and rejection, and
in graft-versus-host disease, through either their tolerogenic
or immunogenic functions, and the maintenance of the
Th1/Th2 balance. The identiﬁcation of population subtypes
with a preference for tolerance or for immune stimulation
will oﬀer targets for immunotherapy and cellular manipu-
lation, to optimize transplant success rates, decreasing early
and late transplant-associated death, as well as primary
disease relapse, prolonging disease-free survival and overall
survival.
Cord blood DC are immature, as a consequence of
necessary maternal-fetal tolerance and fetal immune na¨ ıvet´ e,
which renders them preferentially tolerogenic and, therefore,
theoretically associated with better graft acceptance and
immune reconstitution, while helping to explain the lower
incidence and severity of GvHD in Cb transplantation, even
in the presence of donor-host mismatching.
The ex vivo or in vitro manipulation of DC, through
the induction of maturation and cell loading with speciﬁc
tumor antigens, can direct antitumor immunity and target
minimal residual disease, as demonstrated for acute myeloid
leukemia, optimizing the graft-versus-leukemia eﬀect and
dissociating it from the GvHD.
References
[ 1 ]S .D o u l a t o v ,F .N o t t a ,K .E p p e r t ,L .T .N g u y e n ,P .S .O h a s h i ,
and J. E. Dick, “Revised map of the human progenitor
hierarchy shows the origin of macrophages and dendritic cells
in early lymphoid development,” Nature Immunology, vol. 11,
no. 7, pp. 585–593, 2010.
[2] J. Olweus, A. BitMansour, R. Warnke et al., “Dendritic cell
ontogeny: a human dendritic cell lineage of myeloid origin,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 94, no. 23, pp. 12551–12556, 1997.
[ 3 ]N .C o o l s ,P .P o n s a e r t s ,V .F .I .V a nT e n d e l o o ,a n dZ .N .
Berneman, “Balancing between immunity and tolerance: an
interplay between dendritic cells, regulatory T cells, and
eﬀector T cells,” J o u r n a lo fL e u k o c y t eB i o l o g y , vol. 82, no. 6,
pp. 1365–1374, 2007.
[4] A. Dzionek, A. Fuchs, P. Schmidt et al., “BDCA-2, BDCA-3,
and BDCA-4: three markers for distinct subsets of dendritic
cells in human peripheral blood,” Journal of Immunology, vol.
165, no. 11, pp. 6037–6046, 2000.Stem Cells International 5
[5] J. M. Morgado, R. Pratas, P. Laranjeira et al., “The phenotyp-
ical and functional characteristics of cord blood monocytes
and CD14(-/low)/CD16(+) dendritic cells can be relevant
to the development of cellular immune responses after
transplantation,” Transplant Immunology, vol. 19, no. 1, pp.
55–63, 2008.
[6] R. Thomas and P. E. Lipsky, “Human peripheral blood den-
dritic cell subsets: isolation and characterization of precursor
and mature antigen-presenting cells,” Journal of Immunology,
vol. 153, no. 9, pp. 4016–4028, 1994.
[7] K. Sch¨ a k e l ,E .M a y e r ,C .F e d e r l e ,M .S c h m i t z ,G .R i e t h m¨ uller,
and E. P. Rieber, “A novel dendritic cell population in human
blood: one-step immunomagnetic isolation by a speciﬁc mAb
(M-DC8) and in vitro priming of cytotoxic T lymphocytes,”
European Journal of Immunology, vol. 28, no. 12, pp. 4084–
4093, 1998.
[ 8 ] A .G .J e g a l i a n ,F .F a c c h e t t i ,a n dE .S .J a ﬀe, “Plasmacytoid den-
dritic cells physiologic roles and pathologic states,” Advances
in Anatomic Pathology, vol. 16, no. 6, pp. 392–404, 2009.
[9] X. Yang and X. Gao, “Role of dendritic cells: a step forward for
the hygiene hypothesis,” Cellular and Molecular Immunology,
vol. 8, no. 1, pp. 12–18, 2011.
[10] N. J. Zvaiﬂer, R. M. Steinman, and G. Kaplan, “Identiﬁcation
of immunostimulatory dendritic cells in the synovial eﬀusions
of patients with rheumatoid arthritis,” Journal of Clinical
Investigation, vol. 76, no. 2, pp. 789–800, 1985.
[11] T. Suter, U. Malipiero, L. Otten et al., “Dendritic cells and
diﬀerentialusageoftheMHCclassIItransactivatorpromoters
in the central nervous system in experimental autoimmune
encephalitis,” European Journal of Immunology, vol. 30, no. 3,
pp. 794–802, 2000.
[12] M.-H. Lee, W.-H. Lee, I. Todorov, and C.-P. Liu,
“CD4+CD25+ regulatory T cells prevent type 1 diabetes
preceded by dendritic cell-dominant invasive insulitis by
aﬀecting chemotaxis and local invasiveness of dendritic cells,”
Journal of Immunology, vol. 185, no. 4, pp. 2493–2501, 2010.
[13] A. Berger, “Th1 and Th2 responses: what are they?” British
Medical Journal, vol. 321, no. 7258, p. 424, 2000.
[14] G. E. Kaiko and P. S. Foster, “New insights into the generation
of Th2 immunity and potential therapeutic targets for the
treatment of asthma,” Current Opinion in Allergy and Clinical
Immunology, vol. 11, no. 1, pp. 39–45, 2011.
[15] W. Yao, J. Chang, S. Sehra et al., “Altered cytokine production
by dendritic cells from infants with atopic dermatitis,” Clinical
Immunology, vol. 137, no. 3, pp. 406–414, 2010.
[16] C. M. F. Lima, J. T. Schroeder, C. E. S. Galv˜ ao, F. M. Castro, J.
Kalil, and N. F. Adkinson, “Functional changes of dendritic
cells in hypersensitivity reactions to amoxicillin,” Brazilian
Journal of Medical and Biological Research, vol. 43, no. 10, pp.
964–968, 2010.
[17] S. Romagnani, “Immunologic inﬂuences on allergy and the
T1/T2 balance,” Journal of Allergy and Clinical Immunology,
vol. 113, no. 3, pp. 395–400, 2004.
[18] S. Sozzani, W. Vermi, A. D. Prete, and F. Facchetti, “Traﬃcking
properties of plasmacytoid dendritic cells in health and
disease,” Trends in Immunology, vol. 31, pp. 270–277, 2010.
[19] E. F. Rosloniec, K. Latham, and Y. B. Guedez, “Paradoxical
roles of IFN-γ in models in Th1-mediated autoimmunity,”
Arthritis Research, vol. 4, no. 6, pp. 333–336, 2002.
[20] X. Han, Y. Fan, S. Wang et al., “Dendritic cells from Chlam-
ydia-infected mice show altered Toll-like receptor expression
and play a crucial role in inhibition of allergic responses to
ovalbumin,” European Journal of Immunology, vol. 34, no. 4,
pp. 981–989, 2004.
[ 2 1 ]W .V a nD e nA n c k e r ,M .M .V a nL u i j n ,T .M .W e s t e r se t
al., “Recent advances in antigen-loaded dendritic cell-based
strategies for treatment of minimal residual disease in acute
myeloid leukemia,” Immunotherapy, vol. 2, no. 1, pp. 69–83,
2010.
[22] F. D. Finkelman, A. Lees, R. Birnbaum, W. C. Gause, and S.
C. Morris, “Dendritic cells can present antigen in vivo in a
tolerogenic or immunogenic fashion,” Journal of Immunology,
vol. 157, no. 4, pp. 1406–1414, 1996.
[23] S. Rutella, S. Danese, and G. Leone, “Tolerogenic dendritic
cells: cytokine modulation comes of age,” Blood, vol. 108, no.
5, pp. 1435–1440, 2006.
[24] M. B. Lutz and G. Schuler, “Immature, semi-mature and
fully mature dendritic cells: which signals induce tolerance or
immunity?”TrendsinImmunology,vol.23,no.9,pp.445–449,
2002.
[25] Q. L. Liu, Y. S. Wang, and J. X. Wang, “Eﬀect of growth
hormone on the immune function of dendritic cells,” Chinese
Medical Journal, vol. 123, no. 8, pp. 1078–1083, 2010.
[26] M. Ebrahimi, Z. M. Hassan, J. Hadjati, P. Hayat, and
S. M. Moazzeni, “Immediate exposure to TNF-alpha acti-
vate dendritic cells derived from non-puriﬁed cord blood
mononuclear cells,” Iranian Journal of Immunology, vol. 6, no.
3, pp. 107–118, 2009.
[27] A. Valls, M. Algara, J. Marrugat, E. Carreras, J. Sierra, and
A. Granena, “Risk factors for early mortality in allogeneic
bone marrow transplantation. A multivariate analysis on 174
leukaemia patients,” European Journal of Cancer A, vol. 29, no.
11, pp. 1523–1528, 1993.
[28] G. Soci´ e, J. V. Stone, J. R. Wingard et al., “Long-term survival
and late deaths after allogeneic bone marrow transplantation,”
New England Journal of Medicine, vol. 341, no. 1, pp. 14–21,
1999.
[29] D. Gaziev, M. Galimberti, G. Lucarelli, and P. Polchi, “Chronic
graft-versus-host disease: is there an alternative to the conven-
tional treatment?” Bone Marrow Transplantation, vol. 25, no.
7, pp. 689–696, 2000.
[30] C. L. Toze, A. Galal, M. J. Barnett et al., “Myeloablative
allografting for chronic lymphocytic leukemia: evidence for
a potent graft-versus-leukemia eﬀect associated with graft-
versus-hostdisease,”BoneMarrowTransplantation,vol.36,no.
9, pp. 825–830, 2005.
[31] P. Zhang, B. J. Chen, and N. J. Chao, “Prevention of
GVHD without losing GVL eﬀect: windows of opportunity,”
Immunologic Research, vol. 49, no. 1–3, pp. 49–55, 2011.
[32] M. M. Horowitz, R. P. Gale, P. M. Sondel et al., “Graft-versus-
leukemia reactions after bone marrow transplantation,” Blood,
vol. 75, no. 3, pp. 555–562, 1990.
[ 3 3 ]B .E .A n d e r s o n ,J .M .M c N i ﬀ, C. Matte, I. Athanasiadis, W. D.
Shlomchik, and M. J. Shlomchik, “Recipient CD4+ T cells that
survive irradiation regulate chronic graft-versus-host disease,”
Blood, vol. 104, no. 5, pp. 1565–1573, 2004.
[ 3 4 ]B .E .A n d e r s o n ,J .M .M c N i ﬀ, D. Jain, B. R. Blazar, W.
D. Shlomchik, and M. J. Shlomchik, “Distinct roles for
donor- and host-derived antigen-presenting cells and costim-
ulatorymoleculesinmurinechronicgraft-versus-hostdisease:
requirements depend on target organ,” Blood, vol. 105, no. 5,
pp. 2227–2234, 2005.
[35] M. Nouri-Shirazi and E. Guinet, “Direct and indirect cross-
tolerance of alloreactive T cells by dendritic cells retained in
the immature stage,” Transplantation, vol. 74, no. 7, pp. 1035–
1044, 2002.6 Stem Cells International
[36] M. Maksymowicz, W. L. Olszewski, and E. Cybulska, “Repop-
ulation ofdonorheart byrecipient bonemarrow-derived den-
dritic cells prior to transplantation causes acute rejection by
both the allogeneic and syngeneic recipient,” Transplantation
Proceedings, vol. 35, no. 6, pp. 2374–2375, 2003.
[37] Y. Zhang, J. P. Louboutin, J. Zhu, A. J. Rivera, and S. G.
Emerson, “Preterminal host dendritic cells in irradiated mice
prime CD8+ T cell-mediated acute graft-versus-host disease,”
Journal of Clinical Investigation, vol. 109, no. 10, pp. 1335–
1344, 2002.
[38] H. Galkowska, “Dendritic cells as regulators of immune
reactivity: implications for skin transplantation,” Annals of
Transplantation, vol. 9, no. 2, pp. 5–10, 2004.
[39] H. Hackstein, T. Taner, A. F. Zahorchak et al., “Rapamycin
inhibits IL-4-induced dendritic cell maturation in vitro and
dendritic cell mobilization and function in vivo,” Blood, vol.
101, no. 11, pp. 4457–4463, 2003.
[40] H. Hackstein, T. Taner, A. J. Logar, and A. W. Thom-
son, “Rapamycin inhibits macropinocytosis and mannose
receptor-mediated endocytosis by bone marrow-derived den-
dritic cells,” Blood, vol. 100, no. 3, pp. 1084–1087, 2002.
[41] P. Monti, A. Mercalli, B. Eugenio Leone, D. C. Valerio,
P. Allavena, and L. Piemonti, “Rapamycin impairs antigen
uptake of human dendritic cells,” Transplantation, vol. 75, no.
1, pp. 137–145, 2003.
[42] P. H. Chiang, L. Wang, Y. Liang et al., “Inhibition of IL-12
signalingStat4/IFN-γ pathwaybyrapamycinisassociatedwith
impaired dendritc cell function,” Transplantation Proceedings,
vol. 34, no. 5, pp. 1394–1395, 2002.
[43] A. M. Woltman, J. W. De Fijter, S. W. A. Kamerling
et al., “Rapamycin induces apoptosis in monocyte- and
CD34-derived dendritic cells but not in monocytes and
macrophages,” Blood, vol. 98, no. 1, pp. 174–180, 2001.
[44] A. M. Woltman, S. W. Van der Kooij, P. J. Coﬀer, R. Oﬀringa,
M. R. Daha, and C. Van Kooten, “Rapamycin speciﬁcally
interferes with GM-CSF signaling in human dendritic cells,
leading to apoptosis via increased p27 expression,” Blood, vol.
101, no. 4, pp. 1439–1445, 2003.
[45] P. Klangsinsirikul, G. I. Carter, J. L. Byrne, G. Hale, and N.
H. Russell, “Campath-1G causes rapid depletion of circulating
host dendritic cells (DCs) before allogeneic transplantation
but does not delay donor DC reconstitution,” Blood, vol. 99,
no. 7, pp. 2586–2591, 2002.
[46] K. Sato, N. Yamashita, N. Yamashita, M. Baba, and T.
Matsuyama, “Regulatory dendritic cells protect mice from
murine acute graft-versus-host disease and leukemia relapse,”
Immunity, vol. 18, no. 3, pp. 367–379, 2003.
[47] S. Fujita, Y. Sato, K. Sato et al., “Regulatory dendritic cells
protect against cutaneous chronic graft-versus-host disease
mediated through CD4+CD25+Foxp3+ regulatory T cells,”
Blood, vol. 110, no. 10, pp. 3793–3803, 2007.
[48] K. Sato, K. Eizumi, T. Fukaya et al., “Naturally occurring
regulatory dendritic cells regulate murine cutaneous chronic
graft-versus-host disease,” Blood, vol. 113, no. 19, pp. 4780–
4789, 2009.
[49] Y. Huang, L. D. Bozulic, T. Miller, H. Xu, L.-R. Hussain,
a n dS .T .I l d s t a d ,“ C D 8 α+ plasmacytoid precursor DCs
induce antigen-speciﬁc regulatory T cells that enhance HSC
engraftment in vivo,” Blood, vol. 117, no. 8, pp. 2494–2505,
2011.
[50] I. J. Fugier-Vivier, F. Rezzoug, Y. Huang et al., “Plasmacytoid
precursor dendritic cells facilitate allogeneic hematopoietic
stem cell engraftment,” Journal of Experimental Medicine, vol.
201, no. 3, pp. 373–383, 2005.
[51] A. Encabo, P. Solves, F. Carbonell-Uberos, and M. D. Mi˜ nana,
“The functional immaturity of dendritic cells can be relevant
to increased tolerance associated with cord blood transplanta-
tion,” Transfusion, vol. 47, no. 2, pp. 272–279, 2007.
[ 5 2 ] J .A .H o l l o w a y ,C .A .T h o r n t o n ,N .D .D i a p e r ,D .T .H o w e ,a n d
J.O.Warner,“Phenotypicanalysisofcirculatingdendriticcells
during the second half of human gestation,” Pediatric Allergy
and Immunology, vol. 20, no. 2, pp. 119–125, 2009.
[53] M. Nguyen, E. Leuridan, T. Zhang et al., “Acquisition of adult-
like TLR4 and TLR9 responses during the ﬁrst year of life,”
PLoS ONE, vol. 5, no. 4, Article ID e10407, 2010.
[54] E. M. Clark, D. S. Joshi, A. B. Grimm, A. D. Joshi, P. Wang,
and S. S. Joshi, “Ultrastructural basis of enhanced antitumor
cytotoxicity of cord blood-derived CTLs: a comparative anal-
ysis with peripheral blood and bone marrow,” International
Journal of Oncology, vol. 37, no. 3, pp. 645–653, 2010.
[55] B.Adkins,C.Leclerc,andS.Marshall-Clarke,“Neonataladap-
tiveimmunitycomesofage,”NatureReviewsImmunology,vol.
4, no. 7, pp. 553–564, 2004.
[56] C. B. Wilson, “Immunologic basis for increased susceptibility
of the neonate to infection,” Journal of Pediatrics, vol. 108, no.
1, pp. 1–12, 1986.
[57] M. Makhseed, R. Raghupathy, F. Azizieh, A. Omu, E. Al-
Shamali, and L. Ashkanani, “Th1 and Th2 cytokine proﬁles
in recurrent aborters with successful pregnancy and with
subsequent abortions,” Human Reproduction, vol. 16, no. 10,
pp. 2219–2226, 2001.
[58] A. H. Liu and D. Y. M. Leung, “Renaissance of the hygiene
hypothesis,” Journal of Allergy and Clinical Immunology, vol.
117, no. 5, pp. 1063–1066, 2006.
[ 5 9 ]E .G l u c k m a n ,H .E .B r o x m e y e r ,A .D .A u e r b a c he ta l . ,
“Hematopoietic reconstitution in a patient with Fanconi’s
anemia by means of umbilical-cord blood from an HLA-
identical sibling,” New England Journal of Medicine, vol. 321,
no. 17, pp. 1174–1178, 1989.
[ 6 0 ]J .A .M a d r i g a l ,S .B .A .C o h e n ,E .G l u c k m a n ,a n dD .J .
Charron, “Does cord blood transplantation result in lower
graft-versus-host disease? It takes more than two to tango,”
Human Immunology, vol. 56, no. 1-2, pp. 1–5, 1997.
[61] P. Han, G. Hodge, C. Story, and X. Xu, “Phenotypic analysis
of functional T-lymphocyte subtypes and natural killer cells
in human cord blood: relevance to umbilical cord blood
transplantation,” British Journal of Haematology, vol. 89, no.
4, pp. 733–740, 1995.
[62] M. G. Roncarolo, M. Bigler, E. Ciuti, S. Martino, and P. A.
Tovo,“Immuneresponsesbycordbloodcells,”BloodCells,vol.
20, no. 2-3, pp. 573–586, 1994.
[63] G. Risdon, J. Gaddy, and H. E. Broxmeyer, “Allogeneic
responses of human umbilical cord blood,” Blood Cells, vol.
20, no. 2-3, pp. 566–572, 1994.
[ 6 4 ]J .H .F .F a l k e n b u r g ,S .A .P .V a nL u x e m b u r g - H e i j s ,F .T .H .
Lim, H. H. H. Kanhai, and R. Willemze, “Umbilical cord
blood contains normal frequencies of cytotoxic T-lymphocyte
precursors (ctlp) and helper T-lymphocyte precursors against
noninherited maternal antigens and noninherited paternal
antigens,” Annals of Hematology, vol. 72, no. 4, pp. 260–264,
1996.
[65] S. B. A. Cohen, I. Perez-Cruz, P. Fallen, E. Gluckman, and J.
A. Madrigal, “Analysis of the cytokine production by cord andStem Cells International 7
adult blood,” Human Immunology, vol. 60, no. 4, pp. 331–336,
1999.
[66] A.Rom´ an,M.Rodr´ ıguez,M.A.Herraizetal.,“Heterogeneous
expression of HLA-G1, -G2, -G5, -G6, and -G7 in myeloid
and plasmacytoid dendritic cells isolated from umbilical cord
blood,” Human Immunology, vol. 70, no. 2, pp. 104–109, 2009.
[ 6 7 ]D .W .C .H u n t ,H .I .H u p p e r t z ,H .J .J i a n g ,a n dR .E .P e t t y ,
“Studies of human cord blood dendritic cells: evidence for
functional immaturity,” Blood, vol. 84, no. 12, pp. 4333–4343,
1994.
[ 6 8 ]I .C r e s p o ,A .P a i v a ,A .C o u c e i r o ,P .P i m e n t e l ,A .O r f ˜ ao,
and F. Regateiro, “Immunophenotypic and functional char-
acterization of cord blood dendritic cells,” Stem Cells and
Development, vol. 13, no. 1, pp. 63–70, 2004.
[69] J. Almeida, C. Bueno, M. C. Alguero et al., “Extensive
characterization of the immunophenotype and pattern of
cytokine production by distinct subpopulations of normal
human peripheral blood MHC II+/lineage-cells,” Clinical and
Experimental Immunology, vol. 118, no. 3, pp. 392–401, 1999.
[70] C. Bueno, J. Almeida, M. C. Alguero et al., “Flow cytometric
analysis of cytokine production by normal human peripheral
blood dendritic cells and monocytes: comparative analysis
of diﬀerent stimuli, secretion-blocking agents and incubation
periods,”Communications in Clinical Cytometry, vol. 46, no. 1,
pp. 33–40, 2001.
[71] A. Moretta, R. Maccario, F. Fagioli et al., “Analysis of
immune reconstitution in children undergoing cord blood
transplantation,” Experimental Hematology,v o l .2 9 ,n o .3 ,p p .
371–379, 2001.
[72] F. M. Marty, J. Bryar, S. K. Browne et al., “Sirolimus-
based graft-versus-host disease prophylaxis protects against
cytomegalovirus reactivation after allogeneic hematopoietic
stem cell transplantation: a cohort analysis,” Blood, vol. 110,
no. 2, pp. 490–500, 2007.
[73] K. Beck, U. Meyer-K¨ onig, M. Weidmann, C. Nern, and F.
T. Hufert, “Human cytomegalovirus impairs dendritic cell
function: a novel mechanism of human cytomegalovirus
immune escape,” European Journal of Immunology, vol. 33, no.
6, pp. 1528–1538, 2003.
[74] M. Arpinati, G. Chirumbolo, B. Urbini et al., “Acute graft-
versus-host disease and steroid treatment impair CD11c+
and CD123+ dendritic cell reconstitution after allogeneic
peripheral blood stem cell transplantation,” Biology of Blood
and Marrow Transplantation, vol. 10, no. 2, pp. 106–115, 2004.
[75] S. Yamasaki, Y. Heike, S. Mori et al., “Infectious complications
in chronic graft-versus-host disease: a retrospective study of
145recipients ofallogeneic hematopoietic stemcelltransplan-
tation with reduced- and conventional-intensity conditioning
regimens,” Transplant Infectious Disease,v o l .1 0 ,n o .4 ,p p .
252–259, 2008.
[76] X. C. Wei, X. H. Zhai, X. R. Han, D. D. Yang, and Q. S.
Wang, “Inﬂuence ofdendritic cells on biological activity ofthe
homologous CIK cells and its anti-leukemia eﬀect in vitro,”
Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 18, pp. 946–951,
2010.